Jan 6, 2026
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A...
Jan 6, 2026
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A...
Nov 7, 2025
Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory. There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a...
Nov 7, 2025
Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory. There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a...
Feb 14, 2024
Andrea Pfeifer, Co-Founder, CEO, and Director of AC Immune, is developing vaccines for neurodegenerative disorders such as Alzheimer's and Parkinson's. Unlike vaccines for infectious diseases, these vaccines target internal proteins that are misfolded and contribute to the disease. These new vaccines are active...